La spasticitá è un incremento patologico e velocitádipendente del tono muscolare — dovuto a ipereccitabilitá dei riflessi di stiramento — che si traduce nell’aumentata resistenza ai movimenti passivi, nell’incapacitá di frazionare l’esecuzione del movimento e nell’inappropriata attivitá dei muscoli antagonisti [1].


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Albright AL. Spasticity and movement disorders in cerebral palsy. J Child Neurol 1996; 11(suppl 1):S1–4.PubMedGoogle Scholar
  2. 2.
    Bradley WG, Daroff RB, Fenichel GM et al. Neurology in clinical practise. Butterworth 1989; 1:770–771.Google Scholar
  3. 3.
    Akert K, Buser P, Wiesendanger M, Mosfeldt-Laursen A. Neural control of motor performance. Brain Res 1972; 40:1–203.Google Scholar
  4. 4.
    Ashby P, Andrews C, Knowles L et al. Pyramidal and extrapyramidal control of tonic mechanisms in the cat. Brain 1972; 95:21–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Brooks VB, Stoney SD Jr. Motor mechanisms: the role of the pyramidal system in motor control. Ann Rev Physiol, 1971; 33:337–392.CrossRefGoogle Scholar
  6. 6.
    Rowland LP. Merrit’s textbook of neurology. Lea & Febiger, 1989; 410–411.Google Scholar
  7. 7.
    O’Neil BP, Swanson JW, Brown FR, Griffin JW. Familial spastic paraparesis: an adrenoleukodystrophy phenotype? Neurology 1985; 35:1233–1235.Google Scholar
  8. 8.
    Lees F, Turner JWA. Natural history and prognosis of cervical spondylosis. Brit Med J, 1963; 2:1607–1610.CrossRefPubMedGoogle Scholar
  9. 9.
    Beal MF, Richardson EP. Primary lateral sclerosis: a case report. Arch Neurol 1981; 38:30–33.Google Scholar
  10. 10.
    Boustany R, Fleischnick E, Alper C. The autosomal dominant form of pure spastic paraplegìa. Neurology 1987; 37:910–915.PubMedGoogle Scholar
  11. 11.
    Harding AE. The hereditary ataxias and related disorders. Churchill Livingstone, 1984 pp. 174–190. Per ulteriori approfondimenti si consiglia di consultare il sito web:http://www.ncbi.nlm, Scholar
  12. 12.
    Holmes GL, Shaywitz BA. Sturmpell’s pure familial spastic paraplegìa: case study and review of the literature. J Neurol Neurosurg Psychiatry, 1977; 40:1007–1008.CrossRefGoogle Scholar
  13. 13.
    Johnson AW, McKusick VA. A sex-linked recesive form of spastic paraplegìa. Am J Hum Genet 1962; 14:83–94.Google Scholar
  14. 14.
    Younger DS, Chou S, Hays AP. Primary lateral sclerosis — a clinical diagnosis re-emerges. Arch Neurol 1988; 45:1304–1307.PubMedGoogle Scholar
  15. 15.
    Rosenberg RN, Nyhan WL, Bay C, Shore P. Autosoal dominant striatonigral degeneration. A clinical, pathological and biochemical study of a new genetic disorder. Neurology 1976; 26:703–714.PubMedGoogle Scholar
  16. 16.
    Vatanavicharn N, Pressman BD, Wilcox WR. Reversible leukoencephalopathy with acute neurological deterioration and permanent residua in classical homocystinuria: A case report. J Inherit Metab Dis. 2008 Jan 22.Google Scholar
  17. 17.
    Hata K, Tsuboyama T, Haruta T, Ichihashi N, Kato T, Nakamura T. Relation between muscle thickness, spasticity, and activity limitations in children and adolescents with cerebral palsy. Dev Med Child Neurol, 2008feb; 50 (2): 152–156CrossRefGoogle Scholar
  18. 18.
    -Dones I, Servello D, Molteni F et al. A neurophysiological method for the evaluation of motor performance in spastic walking patients. Acta Neurochir Suppl. 1995; 64:26–29.PubMedGoogle Scholar
  19. 19.
    -Dones I, Nazzi V, Broggi G. The guidelines for the diagnosis and treatment of spasticity. J Neurosurg Sci 2006; Dec. 50(4):101–105.PubMedGoogle Scholar
  20. 20.
    Young RR, Delwaide PJ. Drug therapy: spasticity (second of two parts). N Engl J Med 1981; Jan 8, 304(2): 96–9.PubMedGoogle Scholar
  21. 21.
    Dimitrijevic MR, Sherwood AM. Spasticity: medical and surgical treatment. Neurology 1980; Jul, 30(7 Pt 2):19–27.PubMedGoogle Scholar
  22. 22.
    Siegfried J, Rea GL. Intrathecal application of drugs for muscle hypertonia. Scand J Rehabil Med Suppl 1988; 17:145–148.CrossRefPubMedGoogle Scholar
  23. 23.
    Kamen L, Iii HR, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin 2007; dec. 31.Google Scholar
  24. 24.
    Cherednichenko G, Ward CW, Feng W et al. Enhanced excitation-coupled calcium entry (ECCE) in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene. Molec. Pharmacol 2008, Jan 2.Google Scholar
  25. 25.
    Inder RM, Brogden RN, Speight TM, Avery GS. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs. 1977; Jan, 13(1):3–23.CrossRefGoogle Scholar
  26. 26.
    Tarnawa I, Bölcskei H, Kocsis P. Blockers of voltagegated sodium channels for the treatment of central nervous system diseases. Recent Patents CNS Drug Discov. 2007; Jan, 2(1):57–78.CrossRefGoogle Scholar
  27. 27.
    Benyamina A, Lecacheux M, Blecha L, Reynaud M, Lukasiewcz M. Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. Expert Rev Neurother 2008; Mar, 8(3):479–491. PMID: 18345976 [PubMed — indexed for MEDLINE]CrossRefPubMedGoogle Scholar
  28. 28.
    Yaraskavitch M, Leonard T, Herzog W. Botox produces functional weakness in non-injected muscles adjacent to the target muscle. J Biomech. 2008; 41(9):2067. Epub 2008 May 21.CrossRefGoogle Scholar
  29. 29.
    Gibson N, Graham HK, Love S. Botulinum toxin A in the management of focal muscle overactivity in children with cerebral palsy. Disabil Rehabil. 2007 Dec 15;29(23):1813–1822.CrossRefPubMedGoogle Scholar
  30. 30.
    Turner-Stokes L, Ashford S. Serial injection of botulinum toxin for muscle imbalance due to regional spasticity in the upper limb. Disabil Rehabil 2007; Dec 15, 29(23):1806–1812.CrossRefPubMedGoogle Scholar
  31. 31.
    Hecht MJ, Stolze H, Auf Dem Brinke M, Giess R, Treig T, Winterholler M, Wissel J; German Spasticity Education Group. Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegìa-Report of 19 cases. Mov Disord 2008; Jan 30, 23(2):228–233.CrossRefPubMedGoogle Scholar
  32. 32.
    Decq P. Peripheral neurotomies for the treatment of focal spasticity of the limbs. Neurochirurgie 2003; 49(2–3 Pt 2):293–305. Review French.PubMedGoogle Scholar
  33. 33.
    Dones I. Intrathecal baclofen for the treatment of spasticity. Acta Neurochir Suppl 2007; 97(Pt 1):185–188.PubMedGoogle Scholar
  34. 34.
    Koulousakis A, Kuchta J. Intrathecal antispastic drug application with implantable pumps: results of a 10 year follow-up study. Acta Neurochir Suppl. 2007; 97(Pt 1):181–184.PubMedGoogle Scholar
  35. 35.
    Broggi G, Dones I, Servello D, Ferrazza C. A possible pharmacological treatment of baclofen overdose. Ital J Neurol Sci. 1996 Apr; 17(2):179–180.CrossRefPubMedGoogle Scholar
  36. 36.
    Penn RD. Drug pumps for treatment of neurologic diseases and pain. Neurol Clin. 1985 May; 3(2):439–451.PubMedGoogle Scholar
  37. 37.
    Lazorthes Y, Sallerin-Caute B, Verdie JC, Bastide R. Advances in drug delivery systems and applications in neurosurgery. Adv Tech Stand Neurosurg. 1991; 18:143–192.PubMedGoogle Scholar
  38. 38.
    Ceulemans B, van Rhijn J, Kenis S, Krols R, Laridon A, Van Havenbergh Opisthotonus and intrathecal treatment with baclofen (ITB) in children. Eur J Pediatr. 2007, Aug 24.Google Scholar
  39. 39.
    Motta F, Stignani C, Antonello CE. Upper limb function after intrathecal baclofen treatment in children with cerebral palsy. J Pediatr Orthop. 2008 Jan-Feb; 28(1):91–96.PubMedGoogle Scholar
  40. 40.
    Dones I, Nazzi V, Tringali G et al. Cautious use of intrathecal baclofen in walking spastic patients: results on longterm follow-up. Neuromodulation 2006; 9, 2:87–94.CrossRefGoogle Scholar
  41. 41.
    Hansen CR, Gooch JL, Such-Neibar T. Prolonged, severe intrathecal baclofen withdrawal syndrome: a case report. Arch Phys Med Rehabil. 2007 Nov;88(11):1468–71.CrossRefPubMedGoogle Scholar
  42. 42.
    Albright AL, Tyler-Kabara EC. Combined ventral and dorsal rhizotomies for dystonic and spastic extremities. Report of six cases. J Neurosurg. 2007 Oct; 107(4 Suppl):324–327.PubMedGoogle Scholar
  43. 43.
    Bishop B. Spasticity: its physiology and management. Part IV. Current and projected treatment procedures for spasticity. Phys Ther. 1977 Apr; 57(4):396–401.PubMedGoogle Scholar
  44. 44.
    Bishop B. Spasticity: its physiology and management. Part III. Identifying and assessing the mechanisms underlying spasticity. Phys Ther. 1977 Apr; 57(4):385–395. Review.PubMedGoogle Scholar
  45. 45.
    Bishop B. Spasticity: its physiology and management. Part II. Neurophysiology of spasticity: current concepts. Phys Ther. 1977 Apr;57(4):377–84. Review.PubMedGoogle Scholar
  46. 46.
    Zager EL. Neurosurgical management of spasticity, rigidity, and tremor. Neurol Clin. 1987 Nov; 5(4):631–647.PubMedGoogle Scholar
  47. 47.
    Abbott R, Forem SL, Johann M. Selective posterior rhizotomy for the treatment of spasticity: a review. Childs Nerv Syst. 1989 Dec; 5(6):337–346.CrossRefPubMedGoogle Scholar
  48. 48.
    Peacock WJ, Staudt LA. Selective posterior rhizotomy: evolution of theory and practice. Pediatr Neurosurg. 1991–1992; 17(3):128–134.CrossRefPubMedGoogle Scholar
  49. 49.
    Albright AL. Neurosurgical treatment of spasticity: selective posterior rhizotomy and intrathecal baclofen. Stereotact Funct Neurosurg. 1992; 58(1–4):3–13.CrossRefPubMedGoogle Scholar
  50. 50.
    Walker MJ. Selective dorsal rhizotomy. Reducing spasticity in patients with cerebral palsy. AORN J. 1991 Oct; 54(4):759–61, 764–766, 768–772.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • Ivano Dones
    • 1
  1. 1.Dipartimento di NeurochirurgiaFondazione Istituto Neurologico “C. Besta”Milano

Personalised recommendations